Reimportation is a growing and real concern for the pharmaceutical industry and Congress is considering several bills that seek to make drug importation from Canada legal. What's the best argument against reimportation and is new legislation required?
This article summarizes the results of a recent Pharma Marketing News Survey on this topic. The survey asked the following questions:
- In your opinion, if Congress were to pass one
of the 2 major reimportation bills, which bill would you prefer to be
- Regardless of the fate of bills in Congress,
what's your level of agreement with the following arguments that have
been used against reimportation of prescription drugs?
- Proposed reimportation programs are too
complex and expensive
- FDA cannot guarantee safety of reimported
- Risk of endangering patients with
counterfeit or substandard drugs
- Would hinder the ability of pharmaceutical
companies to invest in R&D for new drugs
- No guarantee reimported drugs would be cheaper after middlemen get their cut